Dimension scores are derived from public data and fields; weighted into the composite. Reference only.
chinaconsun.com is the official website of Consun Pharmaceutical Group, positioned as an information portal for the pharmaceutical company. The site is organized around sections such as “About Consun,” “Product Center,” “R&D Innovation,” “Investor Relations,” and “Corporate News,” showcasing the company’s products and corporate updates in areas including kidney disease, dermatology, bone and trauma care, hepatobiliary and digestive health, women’s and children’s health, and diagnostic imaging. The footer displays its Internet Drug Information Service Qualification Certificate, ICP filing, customer service phone number, email address, and Guangzhou office address. Overall, it is a compliant official website for a pharmaceutical company.
The most important part of the site is the Product Center. It lists products such as Niaoduqing Granules, Yishen Huashi Granules, Gadopentetate Dimeglumine Injection, Iopamidol Injection, Zhenggu Shui, Shiduqing Capsules, and Jigucao Capsules, providing information on ingredients, functions and indications or indications, packaging specifications, dosage and administration, and more. Another key section is Investor Relations, which includes corporate governance, announcements and circulars, periodic reports, stock information, and online shareholders’ meeting guidelines, making it suitable for investors looking up public information on the listed company. The R&D Innovation and Corporate News sections are used to present scientific research achievements, industry-academia-research collaborations, social responsibility initiatives, and industry activities.
The official website does not provide drug retail prices, procurement prices, or online ordering functions, nor does it offer membership subscriptions or paid service models. Its product pages clearly state that the drug information is for introduction of business products only and is not advertising, and that it cannot replace advice from doctors or qualified medical professionals; specific information should be based on the latest version of the package insert. As such, the site functions more as a brand and information disclosure channel than a transaction platform.
The advantages are its broad product coverage, relatively centralized drug information, complete Investor Relations section, clear compliance filings and contact information, making it easy for medical institutions, partners, and investors to quickly verify company information. The drawbacks are that the content follows a fairly traditional corporate website format, the drug instructions are lengthy in layout, and the reading barrier may be high for ordinary patients. Based on the captured content, user service features such as site search, disease education, adverse reaction feedback, and explanations of drug purchase channels do not appear especially prominent. In addition, some news publication dates are shown as 2026, so visitors should verify timeliness for themselves.
The site is suitable for doctors and pharmacists, hospital procurement staff or distribution partners, investors, media, and members of the public who want to learn about Consun Pharmaceutical’s product line. Since the website has a Guangdong ICP filing and domestic drug information service qualification, it is intended for access from mainland China and can usually be reached directly. Individual users should not treat the site’s content as a basis for self-diagnosis or self-medication; prescriptions, dosages, and indications should still follow medical advice.
⚠ This review is compiled from public sources and does not constitute a purchase recommendation. Verify all facts on the vendor's official site. Verify on chinaconsun.com official site.
chinaconsun.com is an China Health provider. TG4G tracks its product information, an overall rating of 6.0/10, and a China-accessibility score of China direct-connect friendly. Click "Visit Official Site" to reach chinaconsun.com directly.